The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Erythropoietin (EPO) Market Research Report 2025
Synopsis
Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. While liver production predominates in the fetal and perinatal period, renal production is predominant during adulthood.
Erythropoietin is an essential hormone for red blood cell production. Without it, definitive erythropoiesis does not take place. Under hypoxic conditions, the kidney will produce and secrete erythropoietin to increase the production of red blood cells by targeting CFU-E, proerythroblast and basophilic erythroblast subsets in the differentiation. Erythropoietin has its primary effect on red blood cell progenitors and precursors (which are found in the bone marrow in humans) by promoting their survival through protecting these cells from apoptosis, or cell death.
In this report, we definite one unit for 1ml, except Epoetin-alfa type, which one unit means 10000units/ml
The global Erythropoietin (EPO) market was valued at US$ 9157.8 million in 2023 and is anticipated to reach US$ 13700 million by 2030, witnessing a CAGR of 5.8% during the forecast period 2024-2030.
The major players in global Erythropoietin market include Amgen, Johnson & Johnson, etc. The top 2 players occupy about 60% shares of the global market. North America is the main market, and occupies over 65% of the global market. Epoetin-alfa is the main type, with a share about 80%. Kidney Disorders is the key application, which holds a share over 40%.
This report aims to provide a comprehensive presentation of the global market for Erythropoietin (EPO), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Erythropoietin (EPO).
Report Scope
The Erythropoietin (EPO) market size, estimations, and forecasts are provided in terms of sales volume (Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Erythropoietin (EPO) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Erythropoietin (EPO) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Amgen
Johnson & Johnson
Roche
Galenica
Emcure
Kyowa Hakko Kirin
3SBio
Biocon
LG Life Sciences
Segment by Type
Epoetin-alfa
Darbepoetin-alfa
Epoetin-beta
Others
Segment by Application
Anemia
Kidney Disorders
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Erythropoietin (EPO) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Erythropoietin (EPO) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. While liver production predominates in the fetal and perinatal period, renal production is predominant during adulthood.
Erythropoietin is an essential hormone for red blood cell production. Without it, definitive erythropoiesis does not take place. Under hypoxic conditions, the kidney will produce and secrete erythropoietin to increase the production of red blood cells by targeting CFU-E, proerythroblast and basophilic erythroblast subsets in the differentiation. Erythropoietin has its primary effect on red blood cell progenitors and precursors (which are found in the bone marrow in humans) by promoting their survival through protecting these cells from apoptosis, or cell death.
In this report, we definite one unit for 1ml, except Epoetin-alfa type, which one unit means 10000units/ml
The global Erythropoietin (EPO) market was valued at US$ 9157.8 million in 2023 and is anticipated to reach US$ 13700 million by 2030, witnessing a CAGR of 5.8% during the forecast period 2024-2030.
The major players in global Erythropoietin market include Amgen, Johnson & Johnson, etc. The top 2 players occupy about 60% shares of the global market. North America is the main market, and occupies over 65% of the global market. Epoetin-alfa is the main type, with a share about 80%. Kidney Disorders is the key application, which holds a share over 40%.
This report aims to provide a comprehensive presentation of the global market for Erythropoietin (EPO), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Erythropoietin (EPO).
Report Scope
The Erythropoietin (EPO) market size, estimations, and forecasts are provided in terms of sales volume (Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Erythropoietin (EPO) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Erythropoietin (EPO) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Amgen
Johnson & Johnson
Roche
Galenica
Emcure
Kyowa Hakko Kirin
3SBio
Biocon
LG Life Sciences
Segment by Type
Epoetin-alfa
Darbepoetin-alfa
Epoetin-beta
Others
Segment by Application
Anemia
Kidney Disorders
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Erythropoietin (EPO) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Erythropoietin (EPO) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Erythropoietin (EPO) Market Overview
1.1 Product Overview and Scope of Erythropoietin (EPO)
1.2 Erythropoietin (EPO) Segment by Type
1.2.1 Global Erythropoietin (EPO) Market Value Comparison by Type (2024-2030)
1.2.2 Epoetin-alfa
1.2.3 Darbepoetin-alfa
1.2.4 Epoetin-beta
1.2.5 Others
1.3 Erythropoietin (EPO) Segment by Application
1.3.1 Global Erythropoietin (EPO) Market Value by Application: (2024-2030)
1.3.2 Anemia
1.3.3 Kidney Disorders
1.3.4 Other
1.4 Global Erythropoietin (EPO) Market Size Estimates and Forecasts
1.4.1 Global Erythropoietin (EPO) Revenue 2019-2030
1.4.2 Global Erythropoietin (EPO) Sales 2019-2030
1.4.3 Global Erythropoietin (EPO) Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Erythropoietin (EPO) Market Competition by Manufacturers
2.1 Global Erythropoietin (EPO) Sales Market Share by Manufacturers (2019-2024)
2.2 Global Erythropoietin (EPO) Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Erythropoietin (EPO) Average Price by Manufacturers (2019-2024)
2.4 Global Erythropoietin (EPO) Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Erythropoietin (EPO), Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Erythropoietin (EPO), Product Type & Application
2.7 Erythropoietin (EPO) Market Competitive Situation and Trends
2.7.1 Erythropoietin (EPO) Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Erythropoietin (EPO) Players Market Share by Revenue
2.7.3 Global Erythropoietin (EPO) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Erythropoietin (EPO) Retrospective Market Scenario by Region
3.1 Global Erythropoietin (EPO) Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Erythropoietin (EPO) Global Erythropoietin (EPO) Sales by Region: 2019-2030
3.2.1 Global Erythropoietin (EPO) Sales by Region: 2019-2024
3.2.2 Global Erythropoietin (EPO) Sales by Region: 2025-2030
3.3 Global Erythropoietin (EPO) Global Erythropoietin (EPO) Revenue by Region: 2019-2030
3.3.1 Global Erythropoietin (EPO) Revenue by Region: 2019-2024
3.3.2 Global Erythropoietin (EPO) Revenue by Region: 2025-2030
3.4 North America Erythropoietin (EPO) Market Facts & Figures by Country
3.4.1 North America Erythropoietin (EPO) Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Erythropoietin (EPO) Sales by Country (2019-2030)
3.4.3 North America Erythropoietin (EPO) Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Erythropoietin (EPO) Market Facts & Figures by Country
3.5.1 Europe Erythropoietin (EPO) Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Erythropoietin (EPO) Sales by Country (2019-2030)
3.5.3 Europe Erythropoietin (EPO) Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Erythropoietin (EPO) Market Facts & Figures by Country
3.6.1 Asia Pacific Erythropoietin (EPO) Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Erythropoietin (EPO) Sales by Country (2019-2030)
3.6.3 Asia Pacific Erythropoietin (EPO) Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Erythropoietin (EPO) Market Facts & Figures by Country
3.7.1 Latin America Erythropoietin (EPO) Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Erythropoietin (EPO) Sales by Country (2019-2030)
3.7.3 Latin America Erythropoietin (EPO) Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Erythropoietin (EPO) Market Facts & Figures by Country
3.8.1 Middle East and Africa Erythropoietin (EPO) Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Erythropoietin (EPO) Sales by Country (2019-2030)
3.8.3 Middle East and Africa Erythropoietin (EPO) Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Erythropoietin (EPO) Sales by Type (2019-2030)
4.1.1 Global Erythropoietin (EPO) Sales by Type (2019-2024)
4.1.2 Global Erythropoietin (EPO) Sales by Type (2025-2030)
4.1.3 Global Erythropoietin (EPO) Sales Market Share by Type (2019-2030)
4.2 Global Erythropoietin (EPO) Revenue by Type (2019-2030)
4.2.1 Global Erythropoietin (EPO) Revenue by Type (2019-2024)
4.2.2 Global Erythropoietin (EPO) Revenue by Type (2025-2030)
4.2.3 Global Erythropoietin (EPO) Revenue Market Share by Type (2019-2030)
4.3 Global Erythropoietin (EPO) Price by Type (2019-2030)
5 Segment by Application
5.1 Global Erythropoietin (EPO) Sales by Application (2019-2030)
5.1.1 Global Erythropoietin (EPO) Sales by Application (2019-2024)
5.1.2 Global Erythropoietin (EPO) Sales by Application (2025-2030)
5.1.3 Global Erythropoietin (EPO) Sales Market Share by Application (2019-2030)
5.2 Global Erythropoietin (EPO) Revenue by Application (2019-2030)
5.2.1 Global Erythropoietin (EPO) Revenue by Application (2019-2024)
5.2.2 Global Erythropoietin (EPO) Revenue by Application (2025-2030)
5.2.3 Global Erythropoietin (EPO) Revenue Market Share by Application (2019-2030)
5.3 Global Erythropoietin (EPO) Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Amgen
6.1.1 Amgen Corporation Information
6.1.2 Amgen Description and Business Overview
6.1.3 Amgen Erythropoietin (EPO) Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Amgen Erythropoietin (EPO) Product Portfolio
6.1.5 Amgen Recent Developments/Updates
6.2 Johnson & Johnson
6.2.1 Johnson & Johnson Corporation Information
6.2.2 Johnson & Johnson Description and Business Overview
6.2.3 Johnson & Johnson Erythropoietin (EPO) Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Johnson & Johnson Erythropoietin (EPO) Product Portfolio
6.2.5 Johnson & Johnson Recent Developments/Updates
6.3 Roche
6.3.1 Roche Corporation Information
6.3.2 Roche Description and Business Overview
6.3.3 Roche Erythropoietin (EPO) Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Roche Erythropoietin (EPO) Product Portfolio
6.3.5 Roche Recent Developments/Updates
6.4 Galenica
6.4.1 Galenica Corporation Information
6.4.2 Galenica Description and Business Overview
6.4.3 Galenica Erythropoietin (EPO) Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Galenica Erythropoietin (EPO) Product Portfolio
6.4.5 Galenica Recent Developments/Updates
6.5 Emcure
6.5.1 Emcure Corporation Information
6.5.2 Emcure Description and Business Overview
6.5.3 Emcure Erythropoietin (EPO) Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Emcure Erythropoietin (EPO) Product Portfolio
6.5.5 Emcure Recent Developments/Updates
6.6 Kyowa Hakko Kirin
6.6.1 Kyowa Hakko Kirin Corporation Information
6.6.2 Kyowa Hakko Kirin Description and Business Overview
6.6.3 Kyowa Hakko Kirin Erythropoietin (EPO) Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Kyowa Hakko Kirin Erythropoietin (EPO) Product Portfolio
6.6.5 Kyowa Hakko Kirin Recent Developments/Updates
6.7 3SBio
6.6.1 3SBio Corporation Information
6.6.2 3SBio Description and Business Overview
6.6.3 3SBio Erythropoietin (EPO) Sales, Revenue and Gross Margin (2019-2024)
6.4.4 3SBio Erythropoietin (EPO) Product Portfolio
6.7.5 3SBio Recent Developments/Updates
6.8 Biocon
6.8.1 Biocon Corporation Information
6.8.2 Biocon Description and Business Overview
6.8.3 Biocon Erythropoietin (EPO) Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Biocon Erythropoietin (EPO) Product Portfolio
6.8.5 Biocon Recent Developments/Updates
6.9 LG Life Sciences
6.9.1 LG Life Sciences Corporation Information
6.9.2 LG Life Sciences Description and Business Overview
6.9.3 LG Life Sciences Erythropoietin (EPO) Sales, Revenue and Gross Margin (2019-2024)
6.9.4 LG Life Sciences Erythropoietin (EPO) Product Portfolio
6.9.5 LG Life Sciences Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Erythropoietin (EPO) Industry Chain Analysis
7.2 Erythropoietin (EPO) Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Erythropoietin (EPO) Production Mode & Process
7.4 Erythropoietin (EPO) Sales and Marketing
7.4.1 Erythropoietin (EPO) Sales Channels
7.4.2 Erythropoietin (EPO) Distributors
7.5 Erythropoietin (EPO) Customers
8 Erythropoietin (EPO) Market Dynamics
8.1 Erythropoietin (EPO) Industry Trends
8.2 Erythropoietin (EPO) Market Drivers
8.3 Erythropoietin (EPO) Market Challenges
8.4 Erythropoietin (EPO) Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
